Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab + Lenvatinib/Axitinib in Advanced ccRCC
NCT07277972Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Feb 2026
- Primary completion
- Nov 2029
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in clear cell renal cell carcinoma (ccRCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07277972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07277972.